Martin Vogel

Publications (49) View all

• Source

  Available from: Axel J Schmidt

  Dataset: Schmidt AJ et al. 2011 PLoS1 Trouble With Bleeding: Risk Factors for Acute Hepatitis C Among HIV-Positive Gay Men From Germany - A Case-Control-Study

  Axel J Schmidt, Jürgen K Rockstroh, Martin Vogel, Matthias An der Heiden, Armin Baillot, Ivanka Krznaric, Doris Radun
• Source

  Available from: Axel J Schmidt

  Dataset: Schmidt A J et al. 2011 PLoS1 Trouble With Bleeding (GermanVersion)

  Axel J Schmidt, Jürgen K Rockstroh, Martin Vogel, Matthias An der Heiden, Armin Baillot, Ivanka Krznaric, Doris Radun
• Article: Reply to Fierer et al.

  Martin Vogel, Emma Page, Christoph Boesecke, Berit Anna Payer, Carolynne Schwarze-Zander, Stefan Mauss, Axel Baumgarten, Jan-Christian Wasmuth, Mark Nelson, Jürgen K Rockstroh
  Clinical Infectious Diseases 06/2012; · 9.15 Impact Factor
• Source

  Available from: Jerzy Jaroszewicz

  Article: Hepatitis B surface antigen concentrations in patients with HIV/HBV co-infection.

  Jerzy Jaroszewicz, Thomas Reiberger, Dirk Meyer-Olson, Stefan Mauss, Martin Vogel, Patrick Ingiliz, Berit Anna Payer, Matthias Stoll, Michael P Manns, Reinhold E Schmidt, Robert Flisiak, Heiner Wedemeyer, Markus Peck-Radosavljevic, Jürgen Rockstroh, Markus Cornberg
  [show abstract] [hide abstract]
  ABSTRACT: HBsAg clearance is associated with clinical cure of chronic hepatitis B virus (HBV) infection. Quantification of HBsAg may help to predict HBsAg clearance during the natural course of HBV infection and during antiviral therapy. Most studies investigating quantitative HBsAg were performed in HBV mono-infected patients. However, the immune status is considered to be important for HBsAg decline and subsequent HBsAg loss. HIV co-infection unfavorably influences the course of chronic hepatitis B. In this cross-sectional study we investigated quantitative HBsAg in 173 HBV/HIV co-infected patients from 6 centers and evaluated the importance of immunodeficiency and antiretroviral therapy. We also compared 46 untreated HIV/HBV infected patients with 46 well-matched HBV mono-infected patients. HBsAg levels correlated with CD4 T-cell count and were higher in patients with more advanced HIV CDC stage. Patients on combination antiretroviral therapy (cART) including nucleos(t)ide analogues active against HBV demonstrated significant lower HBsAg levels compared to untreated patients. Importantly, HBsAg levels were significantly lower in patients who had a stronger increase between nadir CD4 and current CD4 T-cell count during cART. Untreated HIV/HBV patients demonstrated higher HBsAg levels than HBV mono-infected patients despite similar HBV DNA levels. In conclusion, HBsAg decline is dependent on an effective immune status. Restoration of CD4 T-cells during treatment with cART including nucleos(t)ide analogues seems to be important for HBsAg decrease and subsequent HBsAg loss.
  PLoS ONE 01/2012; 7(8):e43143. · 4.09 Impact Factor
• Article: Liver fibrosis progression after acute hepatitis C virus infection in HIV-positive individuals.

  Martin Vogel, Emma Page, Christoph Boesecke, Thomas Reiberger, Carolynne Schwarze-Zander, Stefan Mauss, Axel Baumgarten, J-C Wasmuth, Mark Nelson, Jürgen K Rockstroh
  [show abstract] [hide abstract]
  ABSTRACT: Fibrosis progression after acute hepatitis C virus (HCV) infection in human immunodeficiency virus (HIV)-infected patients with follow-up >9 months became similar to reported rates from studies in chronic HIV/HCV coinfection, as measured with transient elastometry. The duration of follow-up and serum alanine transaminase correlated with liver stiffness, and short follow-up resulted in high fibrosis progression rates.
  Clinical Infectious Diseases 12/2011; 54(4):556-9. · 9.15 Impact Factor